Gene Therapy for Sanfilippo Syndrome Wins FDA Approval After Family’s Fundraising Efforts

A gene therapy for Sanfilippo syndrome Type A won FDA approval in September at a list price of nearly $4 million, after a fundraising campaign by one South Carolina family helped carry the treatment from a mouse lab to the market.

The one-time infusion, called Fayuvi, is the first approved treatment for the rare, fatal genetic disease, which most children do not survive past their teens.

Ultragenyx acquired the rights to the therapy in 2022, submitted data to the Food and Drug Administration, and set the price at nearly $4 million — tying it for the second most expensive gene therapy ever, according to the drug price research firm 46brooklyn.

Behind the approval is a decade of work that families themselves paid for. The Saving Eliza campaign run by the O’Neills of Columbia, S.C., broke GoFundMe’s record at the time in the spring of 2014, raising a million dollars in just a few weeks. That money funded the first human trial, which started in May 2016.

A diagnosis, then a deadline

Eliza O’Neill was 4 when her parents learned she had Sanfilippo syndrome. Cara O’Neill is a pediatrician in Columbia, S.C.

Glenn (from left), Beckham, Cara and Eliza O'Neill pose for a family photo in 2015. Eliza has Sanfilippo syndrome
Photo: knpr.org

“When they said the word, it all kind of came rushing back,” she said. “And it was just this bale of dread, like, oh, my goodness, this is horrific.”

Children with Sanfilippo carry a faulty gene that leaves them unable to break down heparan sulfate, a molecule critical to normal cell function. As it builds up, it damages the brain: children lose the ability to speak and walk, have seizures and usually die before adulthood, the Cure Sanfilippo Foundation says. The O’Neills started the foundation and continue to run it.

For Eliza’s father, Glenn, the weight of that timeline arrived at home.

“It wasn’t really until I got home that I realized how quickly the degeneration happened,” he said. “And that was really the point where we said, ‘Gosh. Whatever we need to do, we need to do it now.’”

made them a video

Families fund Haiyan Fu to continue gene therapy research

The science the families funded traces back to Haiyan Fu, a researcher at Nationwide Children’s Hospital in Columbus, Ohio, who had worked on a Sanfilippo gene therapy in mice since the late-1990s. The therapy uses a modified virus to deliver a working copy of the broken gene to patients’ cells. By 2009, Fu thought she would have to quit. But families of children with the disease kept her lab running.

“They said, ‘You can’t leave. Can we give you some of the funds for you to, you know, carry on?’” Fu said. In all, eight patient foundations, including Ben’s Dream and a Cure for Kirby, supported the work until it was ready for human trials.

“And if we treat early, it could be potentially a cure,” Fu said. “So I can’t give up.”

To raise trial money, Glenn O’Neill turned to an unlikely tool.

Gene Therapy for Sanfilippo Syndrome Wins FDA Approval After Family's Fundraising Efforts
Photo: WBAL News Radio

“We reached out on a whim to some strangers that we found on the internet about making a viral video,” he said. Filmmaker Benjamin Von Wong made the video over a few days in 2014, and the campaign that followed broke the GoFundMe record.

Treating young children remains difficult due to cost and screening

Ultragenyx CEO Emil Kakkis told NPR the treatment works best young — before the brain is lost — and that the company is committed to treating every patient regardless of price.

“By the time they’re 2 or 3 or 4 years old diagnosed, getting figured out, they’ve lost a lot of ground,” Kakkis said, adding that children treated at 6 months of age have done really well.

Cara O’Neill said insurance coverage of the nearly $4 million cost is another hurdle. There is also a screening requirement: children who have been exposed to the virus that carries the gene therapy and built up antibodies above a certain level will not qualify.

The treatment is designed for prevention and stabilization rather than reversal, the O’Neills said. Eliza, treated at 6, had already lost her speech. It never returned. She communicates with picture cards and devices, goes to school and, this summer, learned to float on a pool noodle.

The foundation is also pushing for treatments for the other Sanfilippo types — B, C and D — which the approved therapy does not address.

“These children, regardless of where they live around the country, around the world, deserve access to treatments as soon as possible,” Glenn O’Neill said. A campaign that raised a million dollars in weeks in 2014 ended with an approved therapy priced at nearly $4 million.

Timeline from viral video to FDA approval

  • 2009 — Researcher Haiyan Fu nearly quits; Sanfilippo families fund her lab to continue the gene therapy work.
  • 2013 — Eliza O’Neill is diagnosed with Sanfilippo syndrome.
  • Spring 2014 — The Saving Eliza video helps break GoFundMe’s record, raising a million dollars in just a few weeks.
  • May 2016 — Eliza becomes the first person to receive the experimental gene therapy, in the first human trial.
  • 2022 — Ultragenyx acquires the rights to the therapy.
  • The FDA approves the gene therapy under the name Fayuvi.
Photo of author

Economy Desk

Economy Desk at Archyde.

NRK Director Vibeke Fürst Haugen Responds to Criticism of Reality TV

Samira Said Reveals Identity of Child Singer on New Album Track Matha Law